

## Special Issue

# Vaccine, Molecular Immunology in the Era of Pandemic and Beyond

### Message from the Guest Editors

In the age of the COVID-19 pandemic, vaccine research and development has already saved many lives around the world, but still vaccine-preventable disease continue to cause significant deaths and economic burden globally as well. Therefore, we are pleased to invite you to submit an article to this Special Issue of *Vaccines*, molecular immunology in the era of pandemic and beyond. The objective of this issue is to invite original research articles and reviews to enhance knowledge and better understanding of basic and immune responses after immunization of individuals in health and different ailments. Despite this, we also invite articles submitted on basic and clinical reviews, opinion and commentary pieces, visual pieces, and letters. The manuscripts outside these themes are also welcomed on the cellular, molecular, and behavioral response of vaccines, ethics, safety, and many other related areas. We look forward to receiving your contributions.

---

### Guest Editors

Dr. Vinay Kumar

Dr. Surendra Shukla

Dr. Antresh Kumar

---

### Deadline for manuscript submissions

closed (31 January 2024)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/138199](https://mdpi.com/si/138199)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).